There are more treatments today than ever before to help people with ongoing conditions manage their physical symptoms. But even with these medical advances, a diagnosis of myelodysplastic syndromes ...
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback